1
|
Arshia A, Hassan FA, Hensley PJ, Allison DB. Urinary tract cytology showing variant morphology and divergent differentiation. Cytopathology 2024; 35:199-212. [PMID: 37919868 DOI: 10.1111/cyt.13322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 10/08/2023] [Accepted: 10/13/2023] [Indexed: 11/04/2023]
Abstract
Urothelial carcinoma represents a diverse group of tumours with distinct histologic subtypes, each exhibiting unique cytomorphologic features, architectural growth patterns, and/or well-developed aberrant differentiation. In fact, there are more than 13 subtypes of urothelial carcinoma recognized in the 2022 WHO classification of tumours in the urinary tract. The identification of these subtypes is crucial for an accurate diagnosis of urothelial carcinoma, and many have important clinical implications. Variant/divergent features may coexist with conventional high-grade urothelial carcinoma (HGUC) or present with 100% variant morphology. In urinary tract cytology (UTC), urothelial carcinoma can display divergent differentiation, such as squamous, glandular, or small cell carcinoma differentiation. The use of cell block preparations and immunohistochemistry with available residual urine can enhance diagnostic accuracy. On the other hand, identifying urothelial carcinoma variants, including nested, micropapillary, and plasmacytoid subtypes, poses significant challenges in UTC. Many cases of these variants are only detected retrospectively after variant histology has been established from resection specimens. Moreover, some variants exhibit features inconsistent with the diagnostic criteria for HGUC according to the Paris System for Reporting Urinary Tract Cytology. Nevertheless, the rarity of pure variant morphology and the occurrence of some false negatives for these variant cases are essential to maintain the specificity of UTC overall. This review covers the histology, cytomorphology, and important clinical aspects observed in urothelial carcinoma exhibiting divergent differentiation and various urothelial carcinoma variants detected in UTC.
Collapse
Affiliation(s)
- Asma Arshia
- Department of Pathology and Laboratory Medicine, University of Kentucky College of Medicine, Lexington, Kentucky, USA
| | - Faisal A Hassan
- Department of Pathology and Laboratory Medicine, University of Kentucky College of Medicine, Lexington, Kentucky, USA
| | - Patrick J Hensley
- Markey Cancer Center, Lexington, Kentucky, USA
- Department of Urology, University of Kentucky College of Medicine, Lexington, Kentucky, USA
| | - Derek B Allison
- Department of Pathology and Laboratory Medicine, University of Kentucky College of Medicine, Lexington, Kentucky, USA
- Markey Cancer Center, Lexington, Kentucky, USA
- Department of Urology, University of Kentucky College of Medicine, Lexington, Kentucky, USA
| |
Collapse
|
2
|
Ceachi B, Cioplea M, Mustatea P, Gerald Dcruz J, Zurac S, Cauni V, Popp C, Mogodici C, Sticlaru L, Cioroianu A, Busca M, Stefan O, Tudor I, Dumitru C, Vilaia A, Oprisan A, Bastian A, Nichita L. A New Method of Artificial-Intelligence-Based Automatic Identification of Lymphovascular Invasion in Urothelial Carcinomas. Diagnostics (Basel) 2024; 14:432. [PMID: 38396472 PMCID: PMC10888137 DOI: 10.3390/diagnostics14040432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2024] [Revised: 02/07/2024] [Accepted: 02/14/2024] [Indexed: 02/25/2024] Open
Abstract
The presence of lymphovascular invasion (LVI) in urothelial carcinoma (UC) is a poor prognostic finding. This is difficult to identify on routine hematoxylin-eosin (H&E)-stained slides, but considering the costs and time required for examination, immunohistochemical stains for the endothelium are not the recommended diagnostic protocol. We developed an AI-based automated method for LVI identification on H&E-stained slides. We selected two separate groups of UC patients with transurethral resection specimens. Group A had 105 patients (100 with UC; 5 with cystitis); group B had 55 patients (all with high-grade UC; D2-40 and CD34 immunohistochemical stains performed on each block). All the group A slides and 52 H&E cases from group B showing LVI using immunohistochemistry were scanned using an Aperio GT450 automatic scanner. We performed a pixel-per-pixel semantic segmentation of selected areas, and we trained InternImage to identify several classes. The DiceCoefficient and Intersection-over-Union scores for LVI detection using our method were 0.77 and 0.52, respectively. The pathologists' H&E-based evaluation in group B revealed 89.65% specificity, 42.30% sensitivity, 67.27% accuracy, and an F1 score of 0.55, which is much lower than the algorithm's DCC of 0.77. Our model outlines LVI on H&E-stained-slides more effectively than human examiners; thus, it proves a valuable tool for pathologists.
Collapse
Affiliation(s)
- Bogdan Ceachi
- Department of Pathology, Colentina University Hospital, 21 Stefan Cel Mare Str., Sector 2, 020125 Bucharest, Romania; (B.C.); (M.C.); (C.P.); (C.M.); (L.S.); (A.C.); (M.B.); (O.S.); (I.T.); (C.D.); (A.V.); (A.B.); (L.N.)
- Zaya Artificial Intelligence, 9A Stefan Cel Mare Str., Voluntari, 077190 Ilfov, Romania; (P.M.); (J.G.D.)
- Faculty of Automatic Control and Computer Science, National University of Science and Technology Politehnica Bucharest, 313 Splaiul Independenţei, Sector 6, 060042 Bucharest, Romania
| | - Mirela Cioplea
- Department of Pathology, Colentina University Hospital, 21 Stefan Cel Mare Str., Sector 2, 020125 Bucharest, Romania; (B.C.); (M.C.); (C.P.); (C.M.); (L.S.); (A.C.); (M.B.); (O.S.); (I.T.); (C.D.); (A.V.); (A.B.); (L.N.)
- Zaya Artificial Intelligence, 9A Stefan Cel Mare Str., Voluntari, 077190 Ilfov, Romania; (P.M.); (J.G.D.)
| | - Petronel Mustatea
- Zaya Artificial Intelligence, 9A Stefan Cel Mare Str., Voluntari, 077190 Ilfov, Romania; (P.M.); (J.G.D.)
- Department of Surgery, University of Medicine and Pharmacy Carol Davila, 37 Dionisie Lupu Str., Sector 1, 020021 Bucharest, Romania
| | - Julian Gerald Dcruz
- Zaya Artificial Intelligence, 9A Stefan Cel Mare Str., Voluntari, 077190 Ilfov, Romania; (P.M.); (J.G.D.)
| | - Sabina Zurac
- Department of Pathology, Colentina University Hospital, 21 Stefan Cel Mare Str., Sector 2, 020125 Bucharest, Romania; (B.C.); (M.C.); (C.P.); (C.M.); (L.S.); (A.C.); (M.B.); (O.S.); (I.T.); (C.D.); (A.V.); (A.B.); (L.N.)
- Zaya Artificial Intelligence, 9A Stefan Cel Mare Str., Voluntari, 077190 Ilfov, Romania; (P.M.); (J.G.D.)
- Department of Pathology, University of Medicine and Pharmacy Carol Davila, 37 Dionisie Lupu Str., Sector 1, 020021 Bucharest, Romania;
| | - Victor Cauni
- Department of Urology, Colentina University Hospital, 21 Stefan Cel Mare Str., Sector 2, 020125 Bucharest, Romania
| | - Cristiana Popp
- Department of Pathology, Colentina University Hospital, 21 Stefan Cel Mare Str., Sector 2, 020125 Bucharest, Romania; (B.C.); (M.C.); (C.P.); (C.M.); (L.S.); (A.C.); (M.B.); (O.S.); (I.T.); (C.D.); (A.V.); (A.B.); (L.N.)
- Zaya Artificial Intelligence, 9A Stefan Cel Mare Str., Voluntari, 077190 Ilfov, Romania; (P.M.); (J.G.D.)
| | - Cristian Mogodici
- Department of Pathology, Colentina University Hospital, 21 Stefan Cel Mare Str., Sector 2, 020125 Bucharest, Romania; (B.C.); (M.C.); (C.P.); (C.M.); (L.S.); (A.C.); (M.B.); (O.S.); (I.T.); (C.D.); (A.V.); (A.B.); (L.N.)
- Zaya Artificial Intelligence, 9A Stefan Cel Mare Str., Voluntari, 077190 Ilfov, Romania; (P.M.); (J.G.D.)
| | - Liana Sticlaru
- Department of Pathology, Colentina University Hospital, 21 Stefan Cel Mare Str., Sector 2, 020125 Bucharest, Romania; (B.C.); (M.C.); (C.P.); (C.M.); (L.S.); (A.C.); (M.B.); (O.S.); (I.T.); (C.D.); (A.V.); (A.B.); (L.N.)
- Zaya Artificial Intelligence, 9A Stefan Cel Mare Str., Voluntari, 077190 Ilfov, Romania; (P.M.); (J.G.D.)
| | - Alexandra Cioroianu
- Department of Pathology, Colentina University Hospital, 21 Stefan Cel Mare Str., Sector 2, 020125 Bucharest, Romania; (B.C.); (M.C.); (C.P.); (C.M.); (L.S.); (A.C.); (M.B.); (O.S.); (I.T.); (C.D.); (A.V.); (A.B.); (L.N.)
- Zaya Artificial Intelligence, 9A Stefan Cel Mare Str., Voluntari, 077190 Ilfov, Romania; (P.M.); (J.G.D.)
- Department of Pathology, University of Medicine and Pharmacy Carol Davila, 37 Dionisie Lupu Str., Sector 1, 020021 Bucharest, Romania;
| | - Mihai Busca
- Department of Pathology, Colentina University Hospital, 21 Stefan Cel Mare Str., Sector 2, 020125 Bucharest, Romania; (B.C.); (M.C.); (C.P.); (C.M.); (L.S.); (A.C.); (M.B.); (O.S.); (I.T.); (C.D.); (A.V.); (A.B.); (L.N.)
- Zaya Artificial Intelligence, 9A Stefan Cel Mare Str., Voluntari, 077190 Ilfov, Romania; (P.M.); (J.G.D.)
| | - Oana Stefan
- Department of Pathology, Colentina University Hospital, 21 Stefan Cel Mare Str., Sector 2, 020125 Bucharest, Romania; (B.C.); (M.C.); (C.P.); (C.M.); (L.S.); (A.C.); (M.B.); (O.S.); (I.T.); (C.D.); (A.V.); (A.B.); (L.N.)
| | - Irina Tudor
- Department of Pathology, Colentina University Hospital, 21 Stefan Cel Mare Str., Sector 2, 020125 Bucharest, Romania; (B.C.); (M.C.); (C.P.); (C.M.); (L.S.); (A.C.); (M.B.); (O.S.); (I.T.); (C.D.); (A.V.); (A.B.); (L.N.)
| | - Carmen Dumitru
- Department of Pathology, Colentina University Hospital, 21 Stefan Cel Mare Str., Sector 2, 020125 Bucharest, Romania; (B.C.); (M.C.); (C.P.); (C.M.); (L.S.); (A.C.); (M.B.); (O.S.); (I.T.); (C.D.); (A.V.); (A.B.); (L.N.)
| | - Alexandra Vilaia
- Department of Pathology, Colentina University Hospital, 21 Stefan Cel Mare Str., Sector 2, 020125 Bucharest, Romania; (B.C.); (M.C.); (C.P.); (C.M.); (L.S.); (A.C.); (M.B.); (O.S.); (I.T.); (C.D.); (A.V.); (A.B.); (L.N.)
- Zaya Artificial Intelligence, 9A Stefan Cel Mare Str., Voluntari, 077190 Ilfov, Romania; (P.M.); (J.G.D.)
- Department of Pathology, University of Medicine and Pharmacy Carol Davila, 37 Dionisie Lupu Str., Sector 1, 020021 Bucharest, Romania;
| | - Alexandra Oprisan
- Department of Pathology, University of Medicine and Pharmacy Carol Davila, 37 Dionisie Lupu Str., Sector 1, 020021 Bucharest, Romania;
- Department of Neurology, Colentina University Hospital, 21 Stefan Cel Mare Str., Sector 2, 020125 Bucharest, Romania
| | - Alexandra Bastian
- Department of Pathology, Colentina University Hospital, 21 Stefan Cel Mare Str., Sector 2, 020125 Bucharest, Romania; (B.C.); (M.C.); (C.P.); (C.M.); (L.S.); (A.C.); (M.B.); (O.S.); (I.T.); (C.D.); (A.V.); (A.B.); (L.N.)
- Department of Pathology, University of Medicine and Pharmacy Carol Davila, 37 Dionisie Lupu Str., Sector 1, 020021 Bucharest, Romania;
| | - Luciana Nichita
- Department of Pathology, Colentina University Hospital, 21 Stefan Cel Mare Str., Sector 2, 020125 Bucharest, Romania; (B.C.); (M.C.); (C.P.); (C.M.); (L.S.); (A.C.); (M.B.); (O.S.); (I.T.); (C.D.); (A.V.); (A.B.); (L.N.)
- Zaya Artificial Intelligence, 9A Stefan Cel Mare Str., Voluntari, 077190 Ilfov, Romania; (P.M.); (J.G.D.)
- Department of Pathology, University of Medicine and Pharmacy Carol Davila, 37 Dionisie Lupu Str., Sector 1, 020021 Bucharest, Romania;
| |
Collapse
|
3
|
Park HK. Do Histology and Primary Tumor Location Influence Metastatic Patterns in Bladder Cancer? Curr Oncol 2023; 30:9078-9089. [PMID: 37887556 PMCID: PMC10605465 DOI: 10.3390/curroncol30100656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2023] [Revised: 09/30/2023] [Accepted: 10/10/2023] [Indexed: 10/28/2023] Open
Abstract
Metastasis is the leading cause of death in patients with bladder cancer. This study utilized a statistical analysis of patient data from the Surveillance, Epidemiology, and End Results database to examine the influence of histological type and primary site on the metastatic behavior of bladder cancer. Significantly different metastatic patterns were observed among bladder cancer patients depending on their histological type. Patients with squamous cell carcinoma showed a significantly (p < 0.001) lower bone metastasis rate (27.2%) than patients with urothelial carcinoma (UC) (38.3%). Patients with neuroendocrine carcinoma showed a significantly (p < 0.001) higher liver metastasis rate (52.1%) and a significantly (p = 0.001) lower lung metastasis rate (25.7%) than patients with UC (22.6% and 33.5%, respectively). UC patients also demonstrated differences in metastatic behavior according to histological subtype. The sarcomatoid subtype showed a significantly (p < 0.001) higher lung metastasis rate (51.6%) and a significantly lower (p = 0.002) lymph node metastasis rate (22.6%) than the micropapillary subtype (12.1% and 54.1%, respectively). Significant differences in metastatic behavior were also observed among patients with conventional UCs originating from the bladder, ureter, and renal pelvis. This study highlights the impact of histological characteristics and primary site on metastatic tendencies in bladder cancer, highlighting the importance of tailoring treatment and surveillance strategies.
Collapse
Affiliation(s)
- Hyung Kyu Park
- Department of Pathology, Chungnam National University School of Medicine, Daejeon 35015, Republic of Korea
| |
Collapse
|
4
|
Sato D, Kadota T, Inaba A, Nishihara K, Takashima K, Nakajo K, Sawada K, Kotani D, Fujiwara H, Yoda Y, Kojima T, Fujita T, Fujii S, Yano T. Long-term clinical outcome after endoscopic resection of esophageal squamous cell carcinoma invading the muscularis mucosae without lymphovascular invasion. Gastrointest Endosc 2022; 95:634-641.e3. [PMID: 34774578 DOI: 10.1016/j.gie.2021.11.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/07/2021] [Accepted: 11/02/2021] [Indexed: 02/08/2023]
Abstract
BACKGROUND AND AIMS Lymph node recurrence (LNR) after endoscopic resection (ER) in patients with esophageal squamous cell carcinoma (ESCC) pathologically invading the muscularis mucosae (pMM) without lymphovascular invasion (LVI) has been reported as non-negligible in the ER guidelines for esophageal cancer by the Japan Gastroenterological Endoscopy Society. However, these data were not regarded as high-level evidence because several retrospective case series were tabulated without sufficient long-term follow-up. Hence, this guideline stated that the administration of additional treatment after ER could not be determined for this population. This study aimed to clarify the long-term clinical outcomes after ER of pMM ESCC without LVI. METHODS Between January 2009 and November 2017, we enrolled followed patients who underwent ER and were diagnosed with pMM ESCC without LVI with no additional treatments. We retrospectively investigated the cumulative recurrence rate and recurrence-free, overall, and disease-specific survival at 5 years after ER. RESULTS Eighty-seven patients were enrolled. During the median follow-up period of 64 months (range, 12-117), 3 patients developed lymph node and/or distant recurrence, and 2 of these cases occurred more than 3 years after ER; all 3 patients died of the primary disease. The 5-year cumulative recurrence rate was 4.3%, and the 5-year recurrence-free, disease-specific, and overall survival rates were 88.8%, 98.2%, and 91.7%, respectively. CONCLUSIONS The long-term outcome for patients with pMM ESCC without LVI was favorable after ER; however, this population had a risk of recurrence directly leading to death. Long-term follow-up is necessary, with attention to the timing of recurrence.
Collapse
Affiliation(s)
- Daiki Sato
- Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan; Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan
| | - Tomohiro Kadota
- Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan
| | - Atsushi Inaba
- Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan
| | - Keiichiro Nishihara
- Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan
| | - Kenji Takashima
- Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan
| | - Keiichiro Nakajo
- Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan
| | - Kentaro Sawada
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | - Daisuke Kotani
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | - Hisashi Fujiwara
- Department of Esophageal Surgery, National Cancer Center Hospital East, Kashiwa, Japan
| | - Yusuke Yoda
- Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan
| | - Takashi Kojima
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | - Takeo Fujita
- Department of Esophageal Surgery, National Cancer Center Hospital East, Kashiwa, Japan
| | - Satoshi Fujii
- Division of Pathology, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan; Department of Molecular Pathology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
| | - Tomonori Yano
- Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan
| |
Collapse
|
5
|
Carlsen B, Klingen TA, Andreassen BK, Haug ES. Tumor cell invasion in blood vessels assessed by immunohistochemistry is related to decreased survival in patients with bladder cancer treated with radical cystectomy. Diagn Pathol 2021; 16:109. [PMID: 34809660 PMCID: PMC8609845 DOI: 10.1186/s13000-021-01171-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2021] [Accepted: 11/08/2021] [Indexed: 11/18/2022] Open
Abstract
Background Lymphovascular invasion (VI) is an established prognostic marker for many cancers including bladder cancer. There is a paucity of data regarding whether the prognostic significance of lymphatic invasion (LVI) differs from blood vessel invasion (BVI). The aim was to examine LVI and BVI separately using immunohistochemistry (IHC), and investigate their associations with clinicopathological characteristics and prognosis. A secondary aim was to compare the use of IHC with assessing VI on standard HAS (hematoxylin-azophloxine-saffron) sections without IHC. Methods A retrospective, population –based series of 292 invasive bladder cancers treated with radical cystectomy (RC) with curative intent at Vestfold Hospital Trust, Norway were reviewed. Traditional histopathological markers and VI based on HAS sections were recorded. Dual staining using D2–40/CD31 antibodies was performed on one selected tumor block for each case. Results The frequency of LVI and BVI was 32 and 28%, respectively. BVI was associated with features such as higher pathological stages, positive regional lymph nodes, bladder neck involvement and metastatic disease whereas LVI showed weaker or no associations. Both BVI and LVI independently predicted regional lymph node metastases, LVI being the slightly stronger factor. BVI, not LVI predicted higher pathological stages. BVI showed reduced recurrence free (RFS) and disease specific (DSS) survival in uni-and multivariable analyses, whereas LVI did not. On HAS sections, VI was found in 31% of the cases. By IHC, 51% were positive, corresponding to a 64% increased sensitivity in detecting VI. VI assessed without IHC was significantly associated with RFS and DSS in univariable but not multivariable analysis. Conclusions Our findings indicate that BVI is strongly associated with more aggressive tumor features. BVI was an independent prognostic factor in contrast to LVI. Furthermore, IHC increases VI sensitivity compared to HAS. Supplementary Information The online version contains supplementary material available at 10.1186/s13000-021-01171-7.
Collapse
Affiliation(s)
- Birgitte Carlsen
- Department of Pathology, Vestfold Hospital Trust, Halfdan Wilhelmsens allé 17, N-3103, Tonsberg, Norway.
| | - Tor Audun Klingen
- Department of Pathology, Vestfold Hospital Trust, Halfdan Wilhelmsens allé 17, N-3103, Tonsberg, Norway
| | | | - Erik Skaaheim Haug
- Department of Urology, Vestfold Hospital Trust, Halfdan Wilhelmsens allé 17, N-3103, Tonsberg, Norway
| |
Collapse
|
6
|
Diamantopoulos LN, Holt SK, Khaki AR, Sekar RR, Gadzinski A, Nyame YA, Vakar-Lopez F, Tretiakova MS, Psutka SP, Gore JL, Lin DW, Schade GR, Hsieh AC, Lee JK, Yezefski T, Schweizer MT, Cheng HH, Yu EY, True LD, Montgomery RB, Grivas P, Wright JL. Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program. Clin Genitourin Cancer 2020; 19:144-154. [PMID: 33160889 DOI: 10.1016/j.clgc.2020.10.002] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2020] [Revised: 10/01/2020] [Accepted: 10/04/2020] [Indexed: 01/07/2023]
Abstract
BACKGROUND Micropapillary urothelial carcinoma (MPC) is a rare urothelial carcinoma variant with conflicting data guiding clinical practice. In this study, we explored oncologic outcomes in relation to neoadjuvant chemotherapy (NAC) in a retrospective cohort of patients with MPC, alongside data from Surveillance, Epidemiology, and End Results (SEER)-Medicare. PATIENTS AND METHODS We retrospectively identified patients with MPC or conventional urothelial carcinoma (CUC) without any variant histology undergoing radical cystectomy (RC) in our institution (2003-2018). SEER-Medicare was also queried to identify patients diagnosed with MPC (2004-2015). Clinicopathologic data and treatment modalities were extracted. Overall survival (OS) was estimated with the Kaplan-Meier method. Mann-Whitney-Wilcoxon and chi-square tests were used for comparative analysis and Cox regression for identifying clinical covariates associated with OS. RESULTS Our institutional database yielded 46 patients with MPC and 457 with CUC. In SEER-Medicare, 183 patients with MPC were identified, and 63 (34%) underwent RC. In the institutional cohort, patients with MPC had significantly higher incidence of cN+ (17% vs. 8%), pN+ stage (30% vs. 17%), carcinoma-in-situ (43% vs. 25%), and lymphovascular invasion (30% vs. 16%) at RC versus those with CUC (all P < .05). Pathologic complete response (ypT0N0) to NAC was 33% for MPC and 35% for CUC (P = .899). Median OS was lower for institutional MPC versus CUC in univariate analysis (43.6 vs. 105.3 months, P = .006); however, MPC was not independently associated with OS in the multivariate model. Median OS was 25 months in the SEER MPC cohort for patients undergoing RC, while NAC was not associated with improved OS in that group. CONCLUSION Pathologic response to NAC was not significantly different between MPC and CUC, while MPC histology was not an independent predictor of OS. Further studies are needed to better understand biological mechanisms behind its aggressive features as well as the role of NAC in this histology variant.
Collapse
Affiliation(s)
- Leonidas N Diamantopoulos
- Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA
| | - Sarah K Holt
- Department of Urology, University of Washington, Seattle, WA
| | - Ali R Khaki
- Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA
| | - Rishi R Sekar
- Department of Urology, University of Washington, Seattle, WA
| | - Adam Gadzinski
- Department of Urology, University of Washington, Seattle, WA
| | - Yaw A Nyame
- Department of Urology, University of Washington, Seattle, WA
| | | | | | - Sarah P Psutka
- Department of Urology, University of Washington, Seattle, WA
| | - John L Gore
- Department of Urology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Daniel W Lin
- Department of Urology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - George R Schade
- Department of Urology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Andrew C Hsieh
- Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - John K Lee
- Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Todd Yezefski
- Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA
| | - Michael T Schweizer
- Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Heather H Cheng
- Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Evan Y Yu
- Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Lawrence D True
- Department of Pathology, University of Washington, Seattle, WA
| | - Robert B Montgomery
- Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Petros Grivas
- Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA.
| | - Jonathan L Wright
- Department of Urology, University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA.
| |
Collapse
|
7
|
Abufaraj M, Foerster B, Schernhammer E, Moschini M, Kimura S, Hassler MR, Preston MA, Karakiewicz PI, Remzi M, Shariat SF. Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes. Eur Urol 2019; 75:649-658. [DOI: 10.1016/j.eururo.2018.11.052] [Citation(s) in RCA: 69] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2018] [Accepted: 11/28/2018] [Indexed: 01/01/2023]
|
8
|
Cell Polarity Reversal Distinguishes True Micropapillary Growth From Retraction Artifact in Invasive Urothelial Carcinoma. Appl Immunohistochem Mol Morphol 2018; 26:e1-e6. [PMID: 28800010 DOI: 10.1097/pai.0000000000000566] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Focal micropapillary features in invasive urothelial carcinoma is sometimes difficult to distinguish from retraction artifact morphologically. Cell polarity reversal has been demonstrated in micropapillary tumors by epithelial membrane antigen (EMA) immunostaining. We have previously described the use of E-cadherin as a cell polarity marker in ovarian micropapillary serous borderline tumors. The aim of this study was to evaluate the utility of immunohistochemistry for EMA and E-cadherin in differentiating micropapillary urothelial carcinoma from retraction artifact. We identified 29 invasive urothelial carcinomas with micropapillary features and 30 invasive urothelial carcinomas without reported micropapillary features but with areas of retraction artifact. Cell polarity reversal was considered present if E-cadherin showed membranous apical cup-like staining or if EMA demonstrated a well-defined basal staining towards the stroma. Twenty-seven of 29 cases (93%) of urothelial carcinoma with micropapillary features demonstrated EMA or E-cadherin staining patterns consistent with cell polarity reversal. Staining consistent with micropapillary architecture was identified with both markers in 20 of these 27 cases (74%). Six cases showed reversal of polarity by E-cadherin alone, whereas 1 case showed polarity reversal by EMA alone. Retraction artifacts showed circumferential staining by E-cadherin and lacked well-defined basal staining by EMA. Three cases originally classified as with retraction artifact showed reversal of cell polarity by both EMA and E-cadherin and were reclassified as micropapillary. Our data show that pathologists can reliably make this distinction in most cases. However, in some cases with ambiguous features, EMA and E-cadherin immunostaining may aid in resolving this diagnostic dilemma.
Collapse
|
9
|
Udager AM, McHugh JB, Morgan TM, Spratt DE, Chinnaiyan AM, Mehra R. Utility of ERG Immunohistochemistry for Evaluation of Lymphovascular Invasion in Testicular Germ Cell Tumors: A Retrospective Pilot Study. Appl Immunohistochem Mol Morphol 2017; 27:392-401. [PMID: 28968266 PMCID: PMC5876063 DOI: 10.1097/pai.0000000000000597] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Lymphovascular invasion (LVI) of testicular germ cell tumors (GCT) is an important stage-determining variable in the evaluation of radical orchiectomy specimens. ERG endothelial cell expression, as detected by immunohistochemistry (IHC), robustly highlights lymphovascular spaces, and thus, we sought to assess the utility of ERG IHC for evaluation of GCT LVI. Hematoxylin and eosin (H&E) slides from a retrospective cohort of 25 GCT radical orchiectomy specimens (emanating from a parent cohort of 159 radical orchiectomy GCT cases identified between 2003 and 2013) were reviewed, and sections with foci of positive or equivocal LVI were identified. ERG IHC was performed on sections off the surface of corresponding paraffin tissue blocks. All foci were then rescored as positive, equivocal, or negative for LVI based on ERG endothelial cell expression. Twenty-three and 13 foci were positive or equivocal for LVI by H&E staining, respectively. Among the H&E positive LVI foci, 20 (87%) were ERG IHC positive, whereas of the H&E equivocal LVI foci, 5 (38%) were ERG IHC positive, 3 (23%) were ERG IHC negative, and 2 (15%) were ERG IHC equivocal; all other foci were lost for evaluation. Overall, ERG IHC helped resolve the LVI status of 61% of foci deemed equivocal for LVI by H&E staining only. Although ERG IHC is useful in confirming definitive LVI status in a subset of GCT cases, the overall clinical impact of ERG IHC is limited for H&E equivocal LVI foci in this specific retrospective patient cohort. Overall, in carefully selected clinical scenarios, these data suggest a supportive role for ERG IHC in evaluation of GCT LVI in radical orchiectomy specimens.
Collapse
Affiliation(s)
- Aaron M. Udager
- Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109
| | - Jonathan B. McHugh
- Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109
| | - Todd M. Morgan
- Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109
- Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109
| | - Daniel E. Spratt
- Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI 48109
| | - Arul M. Chinnaiyan
- Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109
- Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109
- Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109
- Michigan Center for Translational Pathology, Ann Arbor, MI 48109
- Howard Hughes Medical Institute, Ann Arbor, MI 48109
| | - Rohit Mehra
- Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109
- Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109
- Michigan Center for Translational Pathology, Ann Arbor, MI 48109
| |
Collapse
|
10
|
Shinagawa T, Hoshino H, Taga M, Sakai Y, Imamura Y, Yokoyama O, Kobayashi M. Clinicopathological implications to micropapillary bladder urothelial carcinoma of the presence of sialyl Lewis X-decorated mucin 1 in stroma-facing membranes. Urol Oncol 2017; 35:606.e17-606.e23. [PMID: 28666720 DOI: 10.1016/j.urolonc.2017.06.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2017] [Revised: 05/01/2017] [Accepted: 06/01/2017] [Indexed: 01/09/2023]
Abstract
OBJECTIVES Bladder urothelial carcinoma (UC) comprises more than 90% of all bladder cancers. Among several UC variants, micropapillary UC (MPUC) is a rare one with high potential for lymphovascular invasion and subsequent lymph node metastasis. Histologically, MPUC is characterized by the presence of small papillary carcinoma cell clusters surrounded by lacunar spaces. Immunohistochemically, the outer circumference of these clusters, that is, the stroma-facing membrane of carcinoma cells, is reportedly almost invariably positive for mucin 1 (MUC1) protein and to a lesser extent for sialyl Lewis X (sLeX) carbohydrates; however, the clinicopathological implications of these expression patterns have not been fully investigated. MATERIALS AND METHODS We performed immunohistochemical analysis of MPUC (n = 11) and conventional UC (n = 57) for MUC1 and sLeX to determine whether these factors immunolocalized. Dual immunofluorescence staining was also carried out to assess MUC1 and sLeX colocalization. We also performed Western blot analysis of Chinese hamster ovary cells misexpressing both recombinant epitope-tagged MUC1 and glycosyltransferases enabling sLeX biosynthesis. RESULTS MPUC samples preferentially exhibited both MUC1 protein and sLeX carbohydrate expression on the stroma-facing membrane of carcinoma cells. Based on univariate analysis, MUC1 expression in that pattern was positively correlated with tumor extension, lymphovascular invasion, lymph node metastasis, disease stage, and relatively poor patient prognosis. A comparable sLeX expression pattern also correlated positively with tumor extension and nodal metastasis. Based on multivariate analysis, localization of MUC1 and sLeX on the stroma-facing side of the membrane was positively correlated with lymph node metastasis. CONCLUSIONS Overall, our immunofluorescence findings as well as immunoprecipitation analyses of Chinese hamster ovary cell transfectants strongly suggest that MUC1 is a potential scaffold protein for sLeX carbohydrates in MPUC. Both MUC1 and sLeX may cooperatively contribute to MPUC histogenesis and clinicopathological characteristics.
Collapse
Affiliation(s)
- Tomochika Shinagawa
- Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan; Department of Urology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan
| | - Hitomi Hoshino
- Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan
| | - Minekatsu Taga
- Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan; Department of Urology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan
| | - Yasuhiro Sakai
- Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan
| | - Yoshiaki Imamura
- Division of Surgical Pathology, University of Fukui Hospital, Eiheiji, Japan
| | - Osamu Yokoyama
- Department of Urology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan
| | - Motohiro Kobayashi
- Department of Tumor Pathology, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan.
| |
Collapse
|
11
|
Li Z, Liao H, Tan Z, Mao D, Wu Y, Xiao YM, Yang SK, Zhong L. Micropapillary bladder cancer: a clinico-pathological characterization and treatment analysis. Clin Transl Oncol 2017; 19:1217-1224. [DOI: 10.1007/s12094-017-1658-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2017] [Accepted: 03/29/2017] [Indexed: 11/29/2022]
|
12
|
Bertz S, Hartmann A, Knüchel-Clarke R, Gaisa NT. [Specific types of bladder cancer]. DER PATHOLOGE 2017; 37:40-51. [PMID: 26782034 DOI: 10.1007/s00292-015-0129-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Bladder cancer shows rare variants and special subtypes with diverse prognostic importance and therefore may necessitate different therapeutic approaches. For pathologists it is important to histologically diagnose and specify such variants. Nested variants of urothelial carcinoma with inconspicuous, well-formed tumor cell nests present with an aggressive course. The plasmacytoid variant, which morphologically resembles plasma cells is associated with a shorter survival time and a high frequency of peritoneal metastasis. Micropapillary urothelial carcinoma with small papillary tumor cell islands within artificial tissue retraction spaces and frequent lymphovascular invasion also has a poor prognosis. Other important rare differential variants listed in the World Health Organization (WHO) classification are microcystic, lymphoepithelioma-like, sarcomatoid, giant cell and undifferentiated urothelial carcinomas. Additionally, there are three special types of bladder cancer: squamous cell carcinoma, adenocarcinoma and small cell neuroendocrine carcinoma of the bladder. These tumors are characterized by pure squamous cell or glandular differentiation and are sometimes less responsive to adjuvant (chemo)therapy. Small cell carcinoma of the bladder mimics the neuroendocrine features of its pulmonary counterpart, shows an aggressive course but is sensitive to (neo-)adjuvant chemotherapy. The morphology and histology of the most important variants and special types are discussed in this review.
Collapse
Affiliation(s)
- S Bertz
- Institut für Pathologie, Universitätsklinikum Erlangen, Krankenhausstrasse 8-10, 91054, Erlangen, Deutschland.
| | - A Hartmann
- Institut für Pathologie, Universitätsklinikum Erlangen, Krankenhausstrasse 8-10, 91054, Erlangen, Deutschland
| | - R Knüchel-Clarke
- Institut für Pathologie, Uniklinikum RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Deutschland
| | - N T Gaisa
- Institut für Pathologie, Uniklinikum RWTH Aachen, Pauwelsstrasse 30, 52074, Aachen, Deutschland.
| |
Collapse
|
13
|
Human epidermal growth factor receptor 2 expression in micropapillary urothelial carcinoma of the bladder: an analysis of 27 cases. Hum Pathol 2016; 57:160-164. [DOI: 10.1016/j.humpath.2016.07.014] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/29/2016] [Revised: 07/04/2016] [Accepted: 07/15/2016] [Indexed: 01/29/2023]
|
14
|
Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy. Virchows Arch 2016; 469:339-44. [PMID: 27392930 DOI: 10.1007/s00428-016-1986-x] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2016] [Revised: 05/27/2016] [Accepted: 07/03/2016] [Indexed: 10/21/2022]
Abstract
Purpose of this study was to evaluate prognostic impact of rare variants of urothelial bladder cancer (BC) after treatment with combined radiochemotherapy (RCT). To this end tumour tissue of 238 patients with urothelial carcinoma (UC) treated with transurethral resection of the bladder (TUR-B) and RCT with curative intent was collected. Histomorphological analysis included re-evaluation and semi-quantitative assessment of rare UC subtypes. Additionally, human epidermal growth factor receptor 2 (HER2) chromogenic in situ hybridisation (CISH) was performed in tumours with a micropapillary component exceeding 30 %. Long-term follow-up was available for 200 patients (range 3-282 months). Variant UC histology was found in 45 of 238 tumours, most frequently micropapillary UC (N = 17) including cases with a small fraction of tumour with micropapillary morphology. The mere presence of micropapillary morphology did not affect prognosis. In tumours with extensive (≥30 %) micropapillary morphology (N = 8) Kaplan-Meier analysis revealed significantly worse cancer specific survival (CSS) (P = 0.002) compared to conventional UC (mean survival times 97 months and 229 months, respectively). Univariate Cox regression analysis of cases with ≥30 % micropapillary morphology revealed a hazard ratio of 4.726 (95 % CI 1.629-13.714) for CSS (P = 0.004). CISH revealed HER2 gene amplification in 3/10 tumours with ≥30 % micropapillary component. In conclusion, for BC treated with TUR-B and RCT, the presence of micropapillary morphology in more than 30 % of the tumour is an adverse prognostic factor. Further studies are needed to evaluate a potential benefit of different, especially multimodal treatment strategies for micropapillary UC and also other subtypes of UC. Her2 represents a promising therapeutic target in a subset of micropapillary UC.
Collapse
|
15
|
Amin MB, Smith SC, Reuter VE, Epstein JI, Grignon DJ, Hansel DE, Lin O, McKenney JK, Montironi R, Paner GP, Al-Ahmadie HA, Algaba F, Ali S, Alvarado-Cabrero I, Bubendorf L, Cheng L, Cheville JC, Kristiansen G, Cote RJ, Delahunt B, Eble JN, Genega EM, Gulmann C, Hartmann A, Langner C, Lopez-Beltran A, Magi-Galluzzi C, Merce J, Netto GJ, Oliva E, Rao P, Ro JY, Srigley JR, Tickoo SK, Tsuzuki T, Umar SA, Van der Kwast T, Young RH, Soloway MS. Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. Mod Pathol 2015; 28:612-30. [PMID: 25412849 PMCID: PMC5009623 DOI: 10.1038/modpathol.2014.158] [Citation(s) in RCA: 80] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2014] [Accepted: 09/02/2014] [Indexed: 12/18/2022]
Abstract
The International Consultations on Urological Diseases are international consensus meetings, supported by the World Health Organization and the Union Internationale Contre le Cancer, which have occurred since 1981. Each consultation has the goal of convening experts to review data and provide evidence-based recommendations to improve practice. In 2012, the selected subject was bladder cancer, a disease which remains a major public health problem with little improvement in many years. The proceedings of the 2nd International Consultation on Bladder Cancer, which included a 'Pathology of Bladder Cancer Work Group,' have recently been published; herein, we provide a summary of developments and consensus relevant to the practicing pathologist. Although the published proceedings have tackled a comprehensive set of issues regarding the pathology of bladder cancer, this update summarizes the recommendations regarding selected issues for the practicing pathologist. These include guidelines for classification and grading of urothelial neoplasia, with particular emphasis on the approach to inverted lesions, the handling of incipient papillary lesions frequently seen during surveillance of bladder cancer patients, descriptions of newer variants, and terminology for urine cytology reporting.
Collapse
Affiliation(s)
- Mahul B Amin
- Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Steven C Smith
- Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - Victor E Reuter
- Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | | | - David J Grignon
- Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Donna E Hansel
- Department of Pathology, University of California San Diego, San Diego, CA, USA
| | - Oscar Lin
- Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - Jesse K McKenney
- Department of Pathology, Cleveland Clinic Foundation, Cleveland, OH, USA
| | - Rodolfo Montironi
- Section of Pathological Anatomy, Polytechnic University of Medicine, United Hospitals, Ancona, Italy
| | - Gladell P Paner
- Department of Pathology, University of Chicago, Chicago, IL, USA
| | - Hikmat A Al-Ahmadie
- Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - Ferran Algaba
- Pathology Section, Fundacio Puigvert, Universitat Autónoma de Barcelona, Barcelona, Spain
| | - Syed Ali
- Department of Pathology, Johns Hopkins Hospital, Baltimore, MD, USA
| | | | - Lukas Bubendorf
- Institute of Pathology, University Hospital Basel, Basel, Switzerland
| | - Liang Cheng
- Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA
| | - John C Cheville
- Division of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA
| | | | - Richard J Cote
- Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Brett Delahunt
- Department of Pathology, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand
| | - John N Eble
- Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Elizabeth M Genega
- Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, MA, USA
| | | | - Arndt Hartmann
- Institute of Pathology, University Erlangen-Nürnberg, Erlangen, Germany
| | - Cord Langner
- Institute of Pathology, Medical University Graz, Graz, Austria
| | - Antonio Lopez-Beltran
- Unit of Anatomical Pathology, Cordoba University Medical School, Faculty of Medicine, Cordoba, Spain
| | | | - Jorda Merce
- Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - George J Netto
- Department of Pathology, Johns Hopkins Hospital, Baltimore, MD, USA
| | - Esther Oliva
- James Homer Wright Pathology Laboratories, Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Priya Rao
- Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
| | - Jae Y Ro
- Department of Pathology and Genomic Medicine, The Methodist Hospital Physician Organization, Weill Cornell Medical College of Cornell University, Houston, TX, USA
| | - John R Srigley
- Department Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
| | - Satish K Tickoo
- Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - Toyonori Tsuzuki
- Department of Pathology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan
| | - Saleem A Umar
- Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Theo Van der Kwast
- Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - Robert H Young
- James Homer Wright Pathology Laboratories, Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Mark S Soloway
- Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA
| |
Collapse
|
16
|
Jackson BL, Mohammed A, Mayer N, Dormer J, Griffiths TRL. Is Immediate Radical Cystectomy Necessary for All Patients with Non-Muscle-Invasive Micropapillary Bladder Cancer? Urol Int 2015; 96:32-8. [PMID: 25924623 DOI: 10.1159/000375411] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2014] [Accepted: 01/20/2015] [Indexed: 11/19/2022]
Abstract
INTRODUCTION We aim to review the outcomes of micropapillary urothelial carcinoma (MPUC) of the bladder from a single institution. The hypothesis is that non-muscle-invasive (NMI) MPUC may have a heterogeneous prognosis, and detailed pathological analysis may identify patients that could be managed without immediate cystectomy. PATIENTS AND METHODS This is a retrospective analysis of patients presenting with MPUC in a primary transurethral resection specimen (n = 40). The pattern of micropapillary (MP) differentiation [surface/non-invasive (sMP) or invasive (iMP)], extent of MP differentiation and lymphovascular invasion (LVI) were correlated with overall survival (OS), recurrence-free survival and upstaging at re-resection. RESULTS Sixteen of 40 patients died after a median follow-up of 37 months. Tumour stage was strongly predictive of OS (p < 0.0001). LVI was associated with increased mortality (hazard ratio 12.4, 95% CI: 3.5-44.5, p = 0.0001), higher pathological stage (p = 0.001), lymph node involvement (p = 0.001) and iMP differentiation (p = 0.006). In NMI patients not undergoing cystectomy (n = 17), NMI-sMP compared with NMI-iMP differentiation was associated with an improved OS when compared with iMP (63 vs. 47 months, p = 0.05). CONCLUSIONS MPUC is an aggressive variant of urothelial carcinoma (UC). Similar to conventional UC, LVI associated with MPUC is an adverse prognostic indicator. iMP is a morphological marker for LVI. Histopathological reports should distinguish between sMP and iMP differentiation.
Collapse
Affiliation(s)
- Benjamin L Jackson
- Department of Urology, University Hospitals of Leicester NHS Trust, Leicester General Hospital, Leicester, UK
| | | | | | | | | |
Collapse
|
17
|
Lu J, Lu N, Xue L, Jin M. Different expression of miRNAs in early esophageal squamous cell carcinoma with differential prognosis. Dis Esophagus 2014; 28:386-93. [PMID: 24697845 DOI: 10.1111/dote.12201] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Patients at the same pathological stage of early esophageal squamous cell carcinoma (ESCC) have significantly different prognoses. The aim of this study was to explore the relationship between specific microRNAs (miRNAs) in two groups of early ESCC patients who had different prognoses at the pT1N0 stage, and to study the prognostic significance of different miRNAs in early ESCC metastasis. We tried to identify prognostic markers that may be helpful in the selection of appropriate treatment for patients with early ESCC. We used TaqMan Human miRNA Arrays to detect and analyze bioinformatically the expression profiles of miRNAs in two groups, and the reverse transcription polymerase chain reaction method to verify the differences in miRNA expression. The miRNA arrays revealed a total of 29 markedly downregulated miRNAs in the survival group compared with the deceased group. Such miRNAs were associated with lympho-vascular invasion and metastasis, and acted as predictive markers of lympho-vascular invasion and metastasis. The detection of these miRNAs forms an important basis for the treatment of early ESCC. It can also help determine those patients with early ESCC who are good candidates for endoscopic resection treatment and those who need additional treatment after endoscopic resection.
Collapse
Affiliation(s)
- J Lu
- Department of Pathology, Beijing Chaoyang Hospital, Capital University, Beijing, China
| | | | | | | |
Collapse
|
18
|
González-Peramato P, Jiménez-Heffernan JA, Vicandi B, López-Ferrer P, Bárcena C, Alvarez-Rodríguez F, Picazo ML, Viguer JM. Micropapillary carcinoma of the urinary tract: a cytologic study of urine and fine-needle aspirate samples. Acta Cytol 2014; 58:269-74. [PMID: 24556948 DOI: 10.1159/000358506] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2013] [Accepted: 01/04/2014] [Indexed: 11/19/2022]
Abstract
OBJECTIVE Micropapillary carcinoma (MPC) is an aggressive variant of urothelial carcinoma that needs early and specific recognition. In order to determine whether this tumor variant can be recognized with cytology, we evaluated a large cytohistological series. STUDY DESIGN It was a retrospective cytohistological correlation study including 20 patients with MPC. Only those cases in which the tumor exhibited >50% of micropapillary growth were selected. Twenty exfoliative urine specimens and four needle aspirates from lymph node metastases were reviewed. RESULTS On histology, 14 cases were infiltrative, while 6 were exclusively superficial. Cytology was characterized by numerous small, cohesive groups and single neoplastic cells. Pseudopapillae were present in 17 cases and in 9 they were a relevant finding. Morules were present in 15 cases. Isolated microacini were seen in 14 cases. Infiltrative tumors showed more neoplastic groups. Cellular atypia was prominent in 17 cases. In 15 cases, a cytologic diagnosis of urothelial carcinoma was made. One case was diagnosed as adenocarcinoma. The remaining 4 cases were considered suspicious of malignancy. CONCLUSIONS The peculiar morphology of MPC of the urinary tract is partially reflected on cytology, allowing in some cases a specific recognition. This is important since the aggressive behavior of this neoplasm needs rapid management and treatment.
Collapse
|
19
|
Ryu HS, Kim WH, Ahn S, Kim DW, Kang SB, Park HJ, Park YS, Lee CH, Lee HS. Combined morphologic and molecular classification for predicting lymph node metastasis in early-stage colorectal adenocarcinoma. Ann Surg Oncol 2014; 21:1809-16. [PMID: 24562932 DOI: 10.1245/s10434-014-3539-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2013] [Indexed: 01/05/2023]
Abstract
BACKGROUND Identifying reliable predictors of lymph node (LN) metastasis is clinically important, particularly for optimizing treatments for early colorectal cancer (ECC) patients. This study evaluated risk-predictive models of LN metastasis using several pathologic and molecular ECC parameters. METHODS Tissue specimens from 179 patients with histologically confirmed ECC were enrolled. A total of 20 clinicopathological characteristics, including tumor budding, micropapillary structure, and mucinous differentiation, and 22 protein expressions related to cancer invasion in central and invasive front areas were evaluated for their predictive value for LN metastasis. RESULTS Alongside conventional histopathological parameters, tumor budding and mucinous differentiation at the invasive front of ECCs and micropapillary structure were found to be independent predictive factors for LN metastasis. Immunohistochemical expressions of CXCL12 and p38-MAPK at the invasive front were also found to be associated with regional LN metastasis in ECC. Analytic logistic models, using combinations of statistically independent parameters, revealed their abilities to predict LN metastasis in ECC. Further, receiver operating characteristic analysis using combinations of 6 or 7 independent variables represented predictive performances (area under curve of 0.956 or 0.960, respectively) for LN metastasis in ECC. CONCLUSIONS The combined histomorphologic and molecular factors tested here might be able to predict for LN metastasis in ECC.
Collapse
Affiliation(s)
- Han Suk Ryu
- Department of Pathology, Seoul National University Hospital, Seoul, South Korea
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Mitobe J, Ikegami M, Urashima M, Takahashi H, Goda K, Tajiri H. Clinicopathological investigation of lymph node metastasis predictors in superficial esophageal squamous cell carcinoma with a focus on evaluation of lympho-vascular invasion. Scand J Gastroenterol 2013; 48:1173-82. [PMID: 23971724 DOI: 10.3109/00365521.2013.832365] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
OBJECTIVE. Reliable indicators of the risk of lymph node metastasis (LNM) in superficial esophageal squamous cell carcinoma (sESCC: intramucosal and submucosal invasive carcinoma) may contribute to assist optimal clinical decision-making for treating sESCC. In esophageal cancer, there is a possibility of metastasis, even in sESCC, and careful evaluation is needed when making a pathological diagnosis. In this study, we objectively evaluated predictive factors of LNM. MATERIALS AND METHODS. A total of 110 consecutive sESCC cases were obtained. We evaluated candidate predictive factors of LNM as follows: (1) maximum tumor diameter; (2) macroscopic type; (3) depth of tumor invasion; (4) histological differentiation; (5) infiltrative growth pattern; (6) tumor budding; (7) lymphatic invasion; (8) venous invasion and (9) lympho-vascular invasion (LVI). Both Elastica-Van Gieson staining (EVG) and immunohistochemistry (IHC: D2-40, CD31, CD34) were used to evaluate invasion into the lympho-vascular spaces. For statistical analyses, single and multiple logistic regression were performed. RESULTS. LNM was observed in 37 cases (33.6%). LVI using EVG and IHC was the strongest independent predictor of LNM with an odds ratio of 12.01. Analysis of the relationship between LVI using EVG and IHC and LNM showed a negative predictive value of 94.6%. CONCLUSIONS. Evaluation of LVI using EVG and IHC may contribute to predict LNM in sESCC.
Collapse
Affiliation(s)
- Jimi Mitobe
- Department of Internal Medicine, Division of Gastroenterology and Hepatology, The Jikei University School of Medicine , Tokyo , Japan
| | | | | | | | | | | |
Collapse
|
21
|
Xiao GQ, Chow J, Maniar KP, Unger PD. Micropapillary variant of embryonal carcinoma: clinicopathological correlation and histochemical study. Int J Surg Pathol 2013; 21:599-602. [PMID: 23842007 DOI: 10.1177/1066896913494794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Micropapillary pattern of growth (MPG) of carcinoma is a unique morphologic pattern. It is uncommon but a predictor of poor outcome. MPG has not been described in any germ cell tumor, most notably embryonal carcinoma, which may have papillary configuration. In this study, we reviewed 25 primary testicular germ cell tumors (pure or mixed) containing embryonal carcinoma and 2 lymph node metastases with embryonal carcinoma. Five of the 25 primary cases demonstrated MPG. With available clinical information, 3/3 (100%) cases with MPG and 5/12 (42%) cases without MPG showed evidence of metastases. The 2 lymph node metastases contained predominantly MPG. At metastasis, the median tumor size in primary tumors with MPG was significantly smaller than in those without MPG. Reticulum staining was negative in the regions of MPG and positive for other coexisting non-micropapillary growth patterns in all the 6 embryonal carcinomas. In conclusion, we described MPG in embryonal carcinoma. Although limited by the number of cases, our clinicopathological correlation results raised the possible association of the presence of MPG to the high-rate metastasis of embryonal carcinoma, similar to that seen in other carcinomas with MPG. It is therefore of importance to document this variant growth pattern if present in embryonal carcinoma. We also demonstrated that reticulum is a useful negative marker for identification of MPG.
Collapse
|